The effect of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online September 23 in the European Heart Journal.

Tasimelteon significantly advanced sleep onset by 42.5 minutes in adults with delayed sleep-wake phase disorder, according to topline phase 3 data.

The expanded indication for mavacamten offers a novel targeted medical therapy for pediatric patients aged 12 years and older with symptomatic oHCM, backed by data from the phase 3 SCOUT-HCM trial.

Phase 3 trial data show that zalunfiban administered on first medical contact significantly improved preprocedural coronary flow and 30-day clinical outcomes in STEMI.

Findings show reductions in inappropriate medication, medication underuse and overuse, and missing vaccinations ...

Highest ASCVD risk at follow-up seen for those who remained in or transitioned into low exposure categories over one year ...

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

A powerful new lab-made opioid is moving through the illegal US drug supply, and federal officials warn it could keep spreading. The drug, called cychlorphine, may be up to 10 times stronger than ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Supported by phase 3 OASIS-4 data, elinzanetant significantly reduced daily hot flash frequency in women receiving endocrine therapy for HR-positive breast cancer.

The oral ALK2 inhibitor significantly reduced mean total new heterotopic ossification volume at 24 weeks in patients aged 12 ...

The new biosimilar offers an additional treatment option for patients with multiple myeloma, bone metastases, and giant cell tumors of the bone.